{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:26:03Z","timestamp":1792016763241,"version":"4.4.0"},"reference-count":174,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>As widely acknowledged, 40\u201350% of all melanoma patients harbour an activating BRAF mutation (mostly BRAF V600E). The identification of the RAS\u2013RAF\u2013MEK\u2013ERK (MAP kinase) signalling pathway and its targeting has represented a valuable milestone for the advanced and, more recently, for the completely resected stage III and IV melanoma therapy management. However, despite progress in BRAF-mutant melanoma treatment, the two different approaches approved so far for metastatic disease, immunotherapy and BRAF+MEK inhibitors, allow a 5-year survival of no more than 60%, and most patients relapse during treatment due to acquired mechanisms of resistance. Deep insight into BRAF gene biology is fundamental to describe the acquired resistance mechanisms (primary and secondary) and to understand the molecular pathways that are now being investigated in preclinical and clinical studies with the aim of improving outcomes in BRAF-mutant patients.<\/jats:p>","DOI":"10.3390\/ijms22073474","type":"journal-article","created":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T22:09:01Z","timestamp":1616969341000},"page":"3474","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":106,"title":["BRAF Gene and Melanoma: Back to the Future"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9589-0808","authenticated-orcid":false,"given":"Margaret","family":"Ottaviano","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Universit\u00e0 Degli Studi di Napoli \u201cFederico II\u201d, 80131 Naples, Italy"},{"name":"Oncology Unit, Ospedale del Mare, 80147 Naples, Italy"},{"name":"CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5383-4469","authenticated-orcid":false,"given":"Emilio","family":"Giunta","sequence":"additional","affiliation":[{"name":"Department of Precision Medicine, Universit\u00e0 Degli Studi della Campania Luigi Vanvitelli, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9853-9594","authenticated-orcid":false,"given":"Marianna","family":"Tortora","sequence":"additional","affiliation":[{"name":"CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Curvietto","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Attademo","sequence":"additional","affiliation":[{"name":"Oncology Unit, Ospedale del Mare, 80147 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bosso","sequence":"additional","affiliation":[{"name":"Oncology Unit, Ospedale del Mare, 80147 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Cardalesi","sequence":"additional","affiliation":[{"name":"Oncology Unit, Ospedale del Mare, 80147 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Rosanova","sequence":"additional","affiliation":[{"name":"Oncology Unit, Ospedale del Mare, 80147 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"De Placido","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Universit\u00e0 Degli Studi di Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2370-2139","authenticated-orcid":false,"given":"Erica","family":"Pietroluongo","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Universit\u00e0 Degli Studi di Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Riccio","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Universit\u00e0 Degli Studi di Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitta","family":"Mucci","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Universit\u00e0 Degli Studi di Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Parola","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine and Surgery, Universit\u00e0 Degli Studi di Napoli \u201cFederico II\u201d, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Vitale","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-6038","authenticated-orcid":false,"given":"Giovannella","family":"Palmieri","sequence":"additional","affiliation":[{"name":"CRCTR Coordinating Rare Tumors Reference Center of Campania Region, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2638-3156","authenticated-orcid":false,"given":"Bruno","family":"Daniele","sequence":"additional","affiliation":[{"name":"Oncology Unit, Ospedale del Mare, 80147 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Simeone","sequence":"additional","affiliation":[{"name":"Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of SCITO YOUTH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2217\/fon-2015-0045","article-title":"The future of melanoma therapy: Developing new drugs and improving the use of old ones","volume":"12","author":"Palumbo","year":"2016","journal-title":"Future Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cribier, B. (2021). Which adjuvant treatment for patients with BRAFV600-mutant cutaneous melanoma?. Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie, Elsevier.","DOI":"10.1016\/j.annder.2021.01.003"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1758835920925219","DOI":"10.1177\/1758835920925219","article-title":"Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations","volume":"12","author":"Giunta","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00428-019-02538-4","article-title":"Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma","volume":"474","author":"Ottaviano","year":"2019","journal-title":"Virchows Arch."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0248-4900(01)01125-X","article-title":"The Raf\/MEK\/ERK pathway: New concepts of activation","volume":"93","author":"Peyssonnaux","year":"2001","journal-title":"Biol. Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"a011254","DOI":"10.1101\/cshperspect.a011254","article-title":"Map kinase pathways","volume":"4","author":"Morrison","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1038\/sj.onc.1210409","article-title":"Role of mitogen-activated protein kinase kinase kinases in signal integration","volume":"26","author":"Cuevas","year":"2007","journal-title":"Oncogene"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/j.str.2015.06.003","article-title":"The RAS-binding domain of human BRAF protein serine\/threonine kinase exhibits allosteric conformational changes upon binding HRAS","volume":"23","author":"Aramini","year":"2015","journal-title":"Structure"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41586-019-1660-y","article-title":"Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes","volume":"575","author":"Park","year":"2010","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-18-1795","article-title":"Class matters: Sensitivity of BRAF-mutant melanoma to MAPK inhibition","volume":"24","author":"Johnson","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","article-title":"BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site","volume":"24","author":"Bauer","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1038\/s41467-019-13161-x","article-title":"Clonal selection confers distinct evolutionary trajectories in BRAF-driven cancers","volume":"10","author":"Gopal","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1479-5876-8-67","article-title":"Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032","volume":"8","author":"Rubinstein","year":"2010","journal-title":"J. Transl. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/bjc.2013.143","article-title":"Rare BRAF mutations in melanoma patients: Implications for molecular testing in clinical practice","volume":"108","author":"Heinzerling","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_20","unstructured":"Cancer Genome Atlas Network (2015). Genomic classification of cutaneous melanoma. Cell, 161, 1681\u20131696."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/1078-0432.CCR-18-1680","article-title":"Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma","volume":"25","author":"Wang","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/CMR.0000000000000388","article-title":"Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma","volume":"27","author":"Li","year":"2017","journal-title":"Melanoma Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/0284186X.2020.1747636","article-title":"BRAF mutational status as a prognostic marker for survival in malignant melanoma: A systematic review and meta-analysis","volume":"59","author":"Ny","year":"2020","journal-title":"Acta Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/bjc.2017.254","article-title":"Tumour mutation status and sites of metastasis in patients with cutaneous melanoma","volume":"117","author":"Adler","year":"2017","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1200\/JCO.19.00489","article-title":"Targeted therapy in advanced melanoma with rare BRAF mutations","volume":"37","author":"Menzer","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1158\/2159-8290.CD-12-0097","article-title":"BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors","volume":"2","author":"Dahlman","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zheng, G., Tseng, L., Chen, G., Haley, L., Illei, P., Gocke, C.D., Eshleman, J.R., and Lin, M.T. (2015). Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. BMC Cancer, 15.","DOI":"10.1186\/s12885-015-1811-y"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS","volume":"548","author":"Yao","year":"2017","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.3892\/ol.2017.6608","article-title":"Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma","volume":"14","author":"Wu","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1158\/0008-5472.CAN-16-2745","article-title":"Engineering and functional characterization of fusion genes identifies novel oncogenic drivers of cancer","volume":"77","author":"Lu","year":"2017","journal-title":"Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.celrep.2019.09.009","article-title":"Genetic heterogeneity of BRAF fusion kinases in melanoma affects drug responses","volume":"29","author":"Botton","year":"2019","journal-title":"Cell Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"103118","DOI":"10.1016\/j.critrevonc.2020.103118","article-title":"BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients","volume":"156","author":"Malapelle","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/jso.25319","article-title":"Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers","volume":"119","author":"Hyams","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000478893","article-title":"Liquid biopsy: Value for melanoma therapy","volume":"40","author":"Machiraju","year":"2017","journal-title":"Oncol. Res. Treat."},{"key":"ref_37","first-page":"405","article-title":"Liquid biopsy to monitor melanoma patients","volume":"16","author":"Gaiser","year":"2018","journal-title":"J. Dermatol. Ges."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12943-018-0757-5","article-title":"Liquid biomarkers in melanoma: Detection and discovery","volume":"17","author":"Lim","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"42008","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Schirosi, L., Strippoli, S., Gaudio, F., Graziano, G., Popescu, O., Guida, M., Simone, G., and Mangia, A. (2016). Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2951-4"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmoldx.2012.09.001","article-title":"Detection of BRAF p.V600E mutations in melanomas: Comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing","volume":"15","author":"Colomba","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamadermatol.2014.3689","article-title":"BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases","volume":"151","author":"Eriksson","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","article-title":"Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma","volume":"37","author":"Long","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/cup.12364","article-title":"Validation of the VE1 immunostain for the BRAF V600E mutation in melanoma","volume":"41","author":"Pearlstein","year":"2014","journal-title":"J. Cutan. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2340\/00015555-2326","article-title":"Highly concordant results between immunohistochemistry and molecular testing of mutated V600E BRAF in primary and metastatic melanoma","volume":"96","author":"Manfredi","year":"2016","journal-title":"Acta Derm. Venereol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.humpath.2014.08.018","article-title":"Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma","volume":"46","author":"Thiel","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Ito, T., Kaku-Ito, Y., Murata, M., Ichiki, T., Kuma, Y., Tanaka, Y., Ide, T., Ohno, F., Wada-Ohno, M., and Yamada, Y. (2019). Intra- and inter-tumor BRAF heterogeneity in acral melanoma: An immunohistochemical analysis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246191"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1373\/clinchem.2005.066068","article-title":"Is the DNA sequence the gold standard in genetic testing? Quality of molecular genetic tests assessed","volume":"52","author":"Bakker","year":"2006","journal-title":"Clin. Chem."},{"key":"ref_49","first-page":"8487","article-title":"Comparison between two widely used laboratory methods in BRAF V600 mutation detection in a large cohort of clinical samples of cutaneous melanoma metastases to the lymph nodes","volume":"8","author":"Jurkowska","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Lopez-Rios, F., Angulo, B., Gomez, B., Mair, D., Martinez, R., Conde, E., Shieh, F., Vaks, J., Langland, R., and Lawrence, H.J. (2013). Comparison of testing methods for the detection of BRAF V600E mutations in malignant melanoma: Pre-approval validation study of the companion diagnostic test for vemurafenib. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0053733"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.jmoldx.2013.07.003","article-title":"Detection of BRAF V600 mutations in metastatic melanoma: Comparison of the Cobas 4800 and Sanger sequencing assays","volume":"15","author":"Qu","year":"2013","journal-title":"J. Mol. Diagn."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Marchant, J., Mange, A., Larrieux, M., Costes, V., and Solassol, J. (2014). Comparative evaluation of the new FDA approved THxID\u2122-BRAF test with high resolution melting and sanger sequencing. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-519"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.5858\/arpa.2011-0505-OA","article-title":"Multisite analytic performance studies of a real-time polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma","volume":"136","author":"Anderson","year":"2012","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mourah, S., Denis, M.G., Narducci, F.E., Solassol, J., Merlin, J.L., Sabourin, J.C., Scoazec, J.Y., Ouafik, L., Emile, J.F., and Heller, R. (2015). Detection of BRAF V600 mutations in melanoma: Evaluation of concordance between the Cobas\u00ae 4800 BRAF V600 mutation test and the methods used in French National Cancer Institute (INCa) platforms in a real-life setting. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120232"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00428-018-2393-2","article-title":"Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma","volume":"473","author":"Zhu","year":"2018","journal-title":"Virchows Arch."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41598-017-00606-w","article-title":"Towards personalized medicine in melanoma: Implementation of a clinical next generation sequencing panel","volume":"7","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1111\/jdv.16294","article-title":"A rare BRAF V600E mutation detected by next-generation sequencing in a superficial spreading melanoma: Case report and potential diagnostic implications","volume":"34","author":"Proietti","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/jamaoncol.2018.2668","article-title":"Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600-mutated metastatic melanoma: Pooled analysis of 4 randomized clinical trials","volume":"4","author":"Hauschild","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): A multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): A multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2019.11.016","article-title":"Update on tolerability and overall survival in COLUMBUS: Landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma","volume":"126","author":"Ascierto","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma Long-Term Therapeutic Outcomes in BRAF-Mutated Melanoma 503 (KEYNOTE-006): Post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma staging: American Joint Committee onCancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/S1470-2045(18)30106-2","article-title":"Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma(BRIM8): A randomised, double-blind, placebo-controlled, multicentre, phase3 trial","volume":"19","author":"Maio","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.18.01219","article-title":"Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600\u2014Mutant stage III melanoma","volume":"36","author":"Hauschild","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S1470-2045(20)30062-0","article-title":"Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): Exploratory biomarker analyses from a randomised, phase 3 trial","volume":"21","author":"Dummer","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/jnci\/djq009","article-title":"Interferon alpha adjuvant therapy inpatients with high-risk melanoma: A systematic review and meta-analysis","volume":"102","author":"Rossi","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0305-7372(03)00074-4","article-title":"Does adjuvant interferon for high-risk melanoma provide a worthwhile bene-fit? A meta-analysis of the randomised trials","volume":"29","author":"Wheatley","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvanttherapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial","volume":"21","author":"Ascierto","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1200\/JCO.20.02110","article-title":"Follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: Updated results from the EORTC 1325-MG\/KEYNOTE-054 Trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo inpatients with resected stage IV melanoma with no evidence of disease (IMMU-NED): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/14737140.2020.1711737","article-title":"Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma","volume":"20","author":"Ziogas","year":"2020","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.phrs.2018.08.019","article-title":"Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy","volume":"136","author":"Kuske","year":"2018","journal-title":"Pharmacol. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1158\/0008-5472.CAN-10-0118","article-title":"Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function","volume":"70","author":"Boni","year":"2010","journal-title":"Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: Effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(20)30934-X","article-title":"Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): Primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial","volume":"395","author":"Gutzmer","year":"2020","journal-title":"Lancet"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/s41591-019-0448-9","article-title":"Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma","volume":"25","author":"Ascierto","year":"2019","journal-title":"Nat. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S1142","DOI":"10.1016\/j.annonc.2020.08.2273","article-title":"LBA43\u2014Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600\u2013mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial","volume":"31","author":"Nathan","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S1173","DOI":"10.1016\/j.annonc.2020.08.2275","article-title":"LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo immuno and targeted therapy study)","volume":"31","author":"Ascierto","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ccell.2014.11.006","article-title":"Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma","volume":"27","author":"Girotti","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.1158\/1078-0432.CCR-18-0836","article-title":"Developments in the space of new MAPK pathway inhibitors for BRAF-mutant melanoma","volume":"25","author":"Cohen","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: Somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/sj.bjc.6605714","article-title":"Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy","volume":"102","author":"Paraiso","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Hartman, M.L., Sztiller-Sikorska, M., Gajos-Michniewicz, A., and Czyz, M. (2020). Dissecting mechanisms of melanoma resistance to BRAF and MEK inhibitors revealed genetic and non-genetic patient- and drug-specific alterations and remarkable phenotypic plasticity. Cells, 9.","DOI":"10.3390\/cells9010142"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Savoia, P., Fava, P., Casoni, F., and Cremona, O. (2019). Targeting the ERK signaling pathway in melanoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061483"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41540-017-0016-1","article-title":"Clinical responses to ERK inhibition in BRAFV600E-mutant colorectal cancer predicted using a computational model","volume":"3","author":"Kirouac","year":"2017","journal-title":"NPJ Syst. Biol. Appl."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Merchant, M., Moffat, J., Schaefer, G., Chan, J., Wang, X., Orr, C., Cheng, J., Hunsaker, T., Shao, L., and Wang, S.J. (2017). Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0185862"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1158\/1538-7445.AM2020-5225","article-title":"Abstract 5225: Temporal inhibition of ERK is sufficient for tumor growth inhibition in KRAS-mutant or BRAF-mutant tumors","volume":"80","author":"Bhagwat","year":"2020","journal-title":"Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"a011189","DOI":"10.1101\/cshperspect.a011189","article-title":"PI3K-PKB\/Akt pathway","volume":"4","author":"Hemmings","year":"2012","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(02)00808-5","article-title":"mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery","volume":"110","author":"Kim","year":"2002","journal-title":"Cell"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/PPO.0b013e31824d448c","article-title":"The role of the PI3K-AKT pathway in melanoma","volume":"18","author":"Davies","year":"2012","journal-title":"Cancer J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/01.cmr.0000200488.77970.e3","article-title":"Mutations of PIK3CA are rare in cutaneous melanoma","volume":"16","author":"Omholt","year":"2006","journal-title":"Melanoma Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/sj.onc.1206451","article-title":"PTEN signaling pathways in melanoma","volume":"22","author":"Wu","year":"2003","journal-title":"Oncogene"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1046\/j.0022-202X.2004.22243.x","article-title":"Genetic interaction between NRAS and BRAF mutations and PTEN\/\/MMAC1 inactivation in melanoma","volume":"122","author":"Tsao","year":"2004","journal-title":"J. Investig. Dermatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1158\/1078-0432.CCR-13-0827","article-title":"Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436)","volume":"19","author":"Nathanson","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Cabrita, R., Mitra, S., Sanna, A., Ekedahl, H., L\u00f6vgren, K., Olsson, H., Ingvar, C., Isaksson, K., Lauss, M., and Carneiro, A. (2020). The role of PTEN loss in immune escape, melanoma prognosis and therapy response. Cancers, 12.","DOI":"10.3390\/cancers12030742"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41389-018-0081-3","article-title":"Oncogenic PI3K\/AKT promotes the step-wise evolution of combination BRAF\/MEK inhibitor resistance in melanoma","volume":"7","author":"Irvine","year":"2018","journal-title":"Oncogenesis"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1038\/s41388-018-0205-4","article-title":"AXL\/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma","volume":"37","author":"Zuo","year":"2018","journal-title":"Oncogene"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/1541-7786.MCR-13-0224-T","article-title":"BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation","volume":"12","author":"Silva","year":"2014","journal-title":"Mol. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e22000","DOI":"10.1200\/JCO.2020.38.15_suppl.e22000","article-title":"Safety results from phase I\/II study of the PI3K\u03b2 inhibitor GSK2636771 (G) in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss","volume":"38","author":"Tawbi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1200\/JCO.2020.38.15_suppl.10022","article-title":"A phase II, multicenter study of encorafenib\/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2)","volume":"38","author":"Dummer","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/pcmr.12777","article-title":"A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600E\/K mutant advanced melanoma","volume":"32","author":"Algazi","year":"2019","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-020-04038-8","article-title":"Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1\/MEK2 inhibitor trametinib in patients with solid tumors","volume":"85","author":"Tolcher","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1158\/2159-8290.CD-15-0894","article-title":"Targeting CDK4 and CDK6: From discovery to therapy","volume":"6","author":"Sherr","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2184.2003.00266.x","article-title":"The cell cycle: A review of regulation, deregulation and therapeutic targets in cancer","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11912-016-0524-y","article-title":"Cell Cycle Regulation and Melanoma","volume":"18","author":"Xu","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Scheiblecker, L., Kollmann, K., and Sexl, V. (2020). CDK4\/6 and MAPK-crosstalk as opportunity for cancer treatment. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120418"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"5238","DOI":"10.1158\/1078-0432.CCR-17-0172","article-title":"Gene expression profiling in BRAF-mutated melanoma reveals patient subgroups with poor outcomes to vemurafenib that may be overcome by cobimetinib plus vemurafenib","volume":"23","author":"Wongchenko","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14656566.2020.1828348","article-title":"Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma","volume":"22","author":"Julve","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1535-7163.MCT-14-0257","article-title":"The CDK4\/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation","volume":"13","author":"Yadav","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"9076","DOI":"10.1200\/jco.2015.33.15_suppl.9076","article-title":"Phase I trial of the CDK 4\/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma","volume":"33","author":"Diab","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"iv374","DOI":"10.1093\/annonc\/mdu344.2","article-title":"1086O\u2014Phase Ib\/II Study of Lee011 (Cdk4\/6 Inhibitor) and Lgx818 (Braf Inhibitor) in Braf-Mutant Melanoma","volume":"25","author":"Taylor","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1002\/ijc.31220","article-title":"Palbociclib synergizes with BRAF and MEK inhibitors in treatment na\u00efve melanoma but not after the development of BRAF inhibitor resistance","volume":"142","author":"Martin","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"661","DOI":"10.21037\/tlcr.2018.08.02","article-title":"Methods of measurement for tumor mutational burden in tumor tissue","volume":"7","author":"Rorive","year":"2018","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13045-019-0787-5","article-title":"Tumor neoantigens: From basic research to clinical applications","volume":"12","author":"Jiang","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s40425-019-0659-0","article-title":"Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma\u2014Results of a prospective biomarker study","volume":"7","author":"Forschner","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to Anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"e21609","DOI":"10.1200\/JCO.2018.36.15_suppl.e21609","article-title":"Associations of age, PD-L1 status, BRAF mutation and tumor mutational burden (TMB) in advanced melanoma","volume":"36","author":"Gibney","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_136","first-page":"185","article-title":"The DNA damaging revolution: PARP inhibitors and beyond","volume":"39","author":"Yap","year":"2019","journal-title":"ASCO Educ. Book"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm1963","article-title":"Poly(ADP-ribose): Novel functions for an old molecule","volume":"7","author":"Schreiber","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2020.06.004","article-title":"The forefront of ovarian cancer therapy: Update on PARP inhibitors","volume":"31","author":"Mirza","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"8109","DOI":"10.1158\/0008-5472.CAN-06-0140","article-title":"Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition","volume":"66","author":"McCabe","year":"2006","journal-title":"Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00286","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1158\/1538-7445.AM2018-320","article-title":"Abstract 320: Frequency and patient characteristics of homologous recombination deficiency in metastatic cutaneous melanoma","volume":"78","author":"Kim","year":"2018","journal-title":"Cancer Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00280-013-2113-1","article-title":"A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation","volume":"71","author":"Plummer","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1093\/annonc\/mdv308","article-title":"Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"eaal5148","DOI":"10.1126\/scitranslmed.aal5148","article-title":"Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers","volume":"9","author":"Sun","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_145","first-page":"1149","article-title":"Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells","volume":"53","author":"Fratangelo","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.semcancer.2017.10.006","article-title":"Epigenetics of malignant melanoma","volume":"51","author":"Moran","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0002-9440(10)64174-0","article-title":"Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase","volume":"161","author":"Straume","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/jid.2009.226","article-title":"Methylation of PTEN as a prognostic factor in malignant melanoma of the skin","volume":"130","author":"Lahtz","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"ref_150","first-page":"34","article-title":"Aberrant DNA methylation in melanoma: Biomarker and therapeutic opportunities","volume":"9","author":"Micevic","year":"2017","journal-title":"Clin. Epi Genet."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/1078-0432.CCR-08-1361","article-title":"CpG island methylator phenotype predicts progression of malignant melanoma","volume":"15","author":"Tanemura","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1073\/pnas.1525619113","article-title":"Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma","volume":"113","author":"Fang","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_153","first-page":"4681","article-title":"Guadecitabine plus ipilimumab in unresectable melanoma: The NIBIT-M4 clinical trial","volume":"14","author":"Covre","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e1500447","DOI":"10.1126\/sciadv.1500447","article-title":"Mammalian SWI\/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics","volume":"1","author":"Kadoch","year":"2015","journal-title":"Sci. Adv."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1615\/CritRevEukaryotGeneExpr.2014007882","article-title":"SWI\/SNF chromatin remodeling enzymes in melanocyte differentiation and melanoma","volume":"24","author":"Mehrotra","year":"2014","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.tig.2014.05.001","article-title":"A rationale to target the SWI\/SNF complex for cancer therapy","volume":"30","author":"Hohmann","year":"2014","journal-title":"Trends Genet."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Milazzo, G., Mercatelli, D., Di Muzio, G., Triboli, L., De Rosa, P., Perini, G., and Giorgi, F.M. (2020). Histone deacetylases (HDACs): Evolution, specificity, role in transcriptional complexes, and pharmacological actionability. Genes, 11.","DOI":"10.3390\/genes11050556"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"16367","DOI":"10.18632\/oncotarget.14829","article-title":"The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib\/dabrafenib-resistant melanoma cells in vitro and in vivo","volume":"8","author":"Booth","year":"2017","journal-title":"Oncotarget"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1158\/0008-5472.CAN-19-0040","article-title":"HDAC8 regulates a stress response pathway in melanoma to mediate escape from BRAF inhibitor therapy","volume":"79","author":"Emmons","year":"2019","journal-title":"Cancer Res."},{"key":"ref_160","first-page":"1429","article-title":"Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long\u2011term BRAF inhibition","volume":"56","author":"Gallagher","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_161","first-page":"24","article-title":"H3K27me3 and EZH2 expression in melanoma: Relevance for melanoma progression and response to immune checkpoint blockade","volume":"12","author":"Hoffmann","year":"2020","journal-title":"Clin. Epi Genet."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Saman, H., Raza, S.S., Uddin, S., and Rasul, K. (2020). Inducing angiogenesis, a key step in cancer vascularization, and treatment approaches. Cancers, 12.","DOI":"10.20944\/preprints202004.0400.v1"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"a006676","DOI":"10.1101\/cshperspect.a006676","article-title":"The role of the tumor microenvironment in regulating angiogenesis","volume":"2","author":"Watnick","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_165","first-page":"546927","article-title":"The roles of angiogenesis in malignant melanoma: Trends in basic science research over the last 100 years","volume":"2012","author":"Dewing","year":"2012","journal-title":"ISRN Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1158\/1078-0432.CCR-14-1554","article-title":"BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth","volume":"21","author":"Wang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12943-019-1090-3","article-title":"AXL receptor tyrosine kinase as a promising anti-cancer approach: Functions, molecular mechanisms and clinical applications","volume":"18","author":"Zhu","year":"2019","journal-title":"Mol Cancer."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"Krijgsman","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1093\/annonc\/mdy229","article-title":"Adjuvant bevacizumab for melanoma patients at high risk of recurrence: Survival analysis of the AVAST-M trial","volume":"29","author":"Corrie","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/CMR.0000000000000146","article-title":"Dacarbazine in combination with bevacizumab for the treatment of unresectable\/metastatic melanoma: A phase II study","volume":"25","author":"Ferrucci","year":"2015","journal-title":"Melanoma Res."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3389\/fimmu.2019.01023","article-title":"Exploring the immunological mechanisms underlying the anti-vascular endothelial growth factor activity in tumors","volume":"10","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41591-019-0482-7","article-title":"Combining checkpoint inhibition and targeted therapy in melanoma","volume":"25","author":"Rozeman","year":"2019","journal-title":"Nat. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol. Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/7\/3474\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T13:32:57Z","timestamp":1760362377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/7\/3474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":174,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["ijms22073474"],"URL":"https:\/\/doi.org\/10.3390\/ijms22073474","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,27]]}}}